EP1516049A4 - Compositions et methodes de traitement et de diagnostic du cancer du poumon - Google Patents

Compositions et methodes de traitement et de diagnostic du cancer du poumon

Info

Publication number
EP1516049A4
EP1516049A4 EP02739247A EP02739247A EP1516049A4 EP 1516049 A4 EP1516049 A4 EP 1516049A4 EP 02739247 A EP02739247 A EP 02739247A EP 02739247 A EP02739247 A EP 02739247A EP 1516049 A4 EP1516049 A4 EP 1516049A4
Authority
EP
European Patent Office
Prior art keywords
diagnosis
compositions
treatment
methods
lung cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02739247A
Other languages
German (de)
English (en)
Other versions
EP1516049A2 (fr
Inventor
Michael J Lodes
Tongtong Wang
Liqun Fan
Paul A Algate
Patricia D Mcneill
Robert A Henderson
Raodoh Moahamath
Heather Secrist
Darin R Benson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corixa Corp
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/854,133 external-priority patent/US6759508B2/en
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of EP1516049A2 publication Critical patent/EP1516049A2/fr
Publication of EP1516049A4 publication Critical patent/EP1516049A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/55—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP02739247A 2001-05-11 2002-05-10 Compositions et methodes de traitement et de diagnostic du cancer du poumon Withdrawn EP1516049A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US854133 2001-05-11
US09/854,133 US6759508B2 (en) 2000-09-01 2001-05-11 Compositions and methods for the therapy and diagnosis of lung cancer
PCT/US2002/014975 WO2002092001A2 (fr) 2001-05-11 2002-05-10 Compositions et methodes de traitement et de diagnostic du cancer du poumon

Publications (2)

Publication Number Publication Date
EP1516049A2 EP1516049A2 (fr) 2005-03-23
EP1516049A4 true EP1516049A4 (fr) 2006-01-11

Family

ID=25317820

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02739247A Withdrawn EP1516049A4 (fr) 2001-05-11 2002-05-10 Compositions et methodes de traitement et de diagnostic du cancer du poumon

Country Status (3)

Country Link
EP (1) EP1516049A4 (fr)
AU (1) AU2002311909A1 (fr)
WO (1) WO2002092001A2 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004016733A2 (fr) 2002-08-16 2004-02-26 Agensys, Inc. Acides nucleiques et proteines correspondantes connues sous 251p5g2 que l'on utilise dans le traitement et la detection de cancers
US7226791B2 (en) * 2003-06-02 2007-06-05 Bristol-Myers Squibb Company Polynucleotides encoding novel guanylate binding proteins (GBP's)
KR101638490B1 (ko) 2008-08-05 2016-07-11 도레이 카부시키가이샤 암의 치료 및 예방용 의약 조성물
BRPI0911925B8 (pt) * 2008-08-05 2024-02-06 Toray Industries Método para detectar um câncer
KR101842893B1 (ko) 2010-02-04 2018-03-28 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
MX342291B (es) 2010-02-04 2016-09-23 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340015B (es) 2010-02-04 2016-06-22 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
BR112012018943A8 (pt) 2010-02-04 2017-12-19 Toray Industries medicamento e método para o tratamento e/ou prevenção de um câncer
HUE025678T2 (en) 2010-02-04 2016-04-28 Toray Industries A pharmaceutical composition for the treatment and / or prevention of cancer
RU2598258C2 (ru) 2010-02-04 2016-09-20 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики рака
US9181348B2 (en) 2011-08-04 2015-11-10 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
PT2740793T (pt) 2011-08-04 2018-02-23 Toray Industries Composição de fármacos para o tratamento e/ou a prevenção de cancro
RU2595400C2 (ru) 2011-08-04 2016-08-27 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли
JP6070191B2 (ja) 2011-08-04 2017-02-01 東レ株式会社 癌の治療及び／又は予防用医薬組成物
KR102041832B1 (ko) 2011-08-04 2019-11-08 도레이 카부시키가이샤 췌장암의 치료 및/또는 예방용 의약 조성물
PT2740794T (pt) 2011-08-04 2018-06-14 Toray Industries Composição farmacêutica para o tratamento e/ou profilaxia de cancro
BR112014002616B1 (pt) 2011-08-04 2022-01-18 Toray Industries, Inc Método para detectar câncer pancreático
PT2818483T (pt) 2012-02-21 2017-10-09 Toray Industries Composição medicinal para tratamento e/ou prevenção de cancro
HUE044611T2 (hu) 2012-02-21 2019-11-28 Toray Industries Gyógyászati készítmény rák kezelésére
US9260513B2 (en) 2012-02-21 2016-02-16 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
BR112014021103A2 (pt) 2012-02-21 2019-10-15 Toray Industries, Inc Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo
PT2832366T (pt) 2012-03-30 2018-01-25 Toray Industries Composição farmacêutica para o tratamento e/ou a prevenção de cancro de vesícula biliar
KR102155531B1 (ko) 2012-03-30 2020-09-15 도레이 카부시키가이샤 간암의 치료 및/또는 예방용 의약 조성물
RU2646466C2 (ru) 2012-07-19 2018-03-05 Торэй Индастриз, Инк. Метод детекции рака
PL2876447T3 (pl) 2012-07-19 2020-05-18 Toray Industries, Inc. Sposób wykrywania nowotworu
ES2704909T3 (es) 2013-08-09 2019-03-20 Toray Industries Composición farmacéutica para el tratamiento y/o la prevención del cáncer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000828A2 (fr) * 1999-06-30 2001-01-04 Corixa Corporation Compositions et techniques de therapie et de diagnostic du cancer du poumon
WO2001072295A2 (fr) * 2000-03-29 2001-10-04 Corixa Corporation Compositions et methodes pouvant traiter ou diagnostiquer le cancer du poumon
WO2001096390A2 (fr) * 2000-06-09 2001-12-20 Corixa Corporation Compositions et procedes pour la therapie et le diagnostic du cancer du colon

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968770A (en) * 1995-02-10 1999-10-19 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of cardiovascular disease using rchd523 as a target

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000828A2 (fr) * 1999-06-30 2001-01-04 Corixa Corporation Compositions et techniques de therapie et de diagnostic du cancer du poumon
WO2001072295A2 (fr) * 2000-03-29 2001-10-04 Corixa Corporation Compositions et methodes pouvant traiter ou diagnostiquer le cancer du poumon
WO2001096390A2 (fr) * 2000-06-09 2001-12-20 Corixa Corporation Compositions et procedes pour la therapie et le diagnostic du cancer du colon

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL 2 May 2001 (2001-05-02), "Homo sapiens cystine/glutamate transporter xCT mRNA", XP002337270, retrieved from EBI Database accession no. AF252872 *
DATABASE EMBL 5 August 1999 (1999-08-05), "Seq ID no: 3414", XP002337271, retrieved from EBI Database accession no. AAZ15945 *
DATABASE EMBL XP002337272, retrieved from EBI Database accession no. AAZ12811 *

Also Published As

Publication number Publication date
WO2002092001A3 (fr) 2005-01-13
WO2002092001A2 (fr) 2002-11-21
AU2002311909A1 (en) 2002-11-25
EP1516049A2 (fr) 2005-03-23

Similar Documents

Publication Publication Date Title
EP1516049A4 (fr) Compositions et methodes de traitement et de diagnostic du cancer du poumon
EP1692318A4 (fr) Compositions et methodes pour le diagnostic et le traitement du cancer du poumon
EP1515982A4 (fr) Methodes et compositions pour la therapie et le diagnostic du cancer de la prostate
EP1639090A4 (fr) Compositions et methodes de traitement et de diagnostic du cancer
EP1583504A4 (fr) Methodes et compositions pour le diagnostic, le pronostic, et le traitement du cancer
EP1589933A4 (fr) Compositions et methodes pour le diagnostic et le traitement d'une tumeur
NO20016427L (no) Blandinger og fremgangsmåter for behandling av diagnose av lungekreft
EP1578371A4 (fr) Compositions et methodes de diagnostic et de traitement des tumeurs
EP1572091A4 (fr) Compositions et methodes de diagnostic et de traitement de tumeurs
EP1553912A4 (fr) Compositions et methodes pour le diagnostic et pour le traitement d'une tumeur
EP1578380A4 (fr) Compositions et procedes pour la therapie et le diagnostic du cancer de la prostate
EP1438062A4 (fr) Methodes et compositions pour le traitement de lesions cutanees
EP1578347A4 (fr) Compositions et procedes pour la detection, le diagnostic et la therapie de malignites hematologiques
EP1578385A4 (fr) Compositions et procedes pour le diagnostic et le traitement d'affections intestinales inflammatoires
EP1539251A4 (fr) Compositions et methodes permettant le diagnostic et le traitement d'etats pathologiques impliquant l'angiogenese
EP1590433A4 (fr) Diagnostic et pronostic de patients souffrant de cancer du sein
EP1575571A4 (fr) Compositions et methodes de diagnostic et de traitement d'une tumeur
EP1756137A4 (fr) Methodes diagnostiques et therapeutiques et compositions impliquant des pten et le cancer du sein
EP1578354A4 (fr) Cibles, procedes et reactifs pour le diagnostic et le traitement de la schizophrenie
EP1446013A4 (fr) Compositions et methodes de traitement et de diagnostic du cancer des poumons
EP1889058A4 (fr) Diagnostic et traitement de l'endométriose
EP1608967A4 (fr) Compositions et procedes pour le diagnostic et le traitement de tumeurs
EP1756166A4 (fr) Diagnostic et traitement du cancer de la prostate
EP1626711A4 (fr) Compositions et methodes de traitement anticancereux
EP1420814A4 (fr) Compositions et techniques de therapie et de diagnostic du cancer du sein

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20031211

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1075674

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20051123

17Q First examination report despatched

Effective date: 20061110

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090122

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1075674

Country of ref document: HK